DK0482076T3 - Stabile vaccinepræparater indeholdende interleukiner - Google Patents

Stabile vaccinepræparater indeholdende interleukiner

Info

Publication number
DK0482076T3
DK0482076T3 DK90911344.1T DK90911344T DK0482076T3 DK 0482076 T3 DK0482076 T3 DK 0482076T3 DK 90911344 T DK90911344 T DK 90911344T DK 0482076 T3 DK0482076 T3 DK 0482076T3
Authority
DK
Denmark
Prior art keywords
preparations containing
vaccine preparations
interleukin
mineral
interleukins
Prior art date
Application number
DK90911344.1T
Other languages
Danish (da)
English (en)
Inventor
Subramonia Pillai
Garvin Bixler
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of DK0482076T3 publication Critical patent/DK0482076T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK90911344.1T 1989-07-14 1990-07-16 Stabile vaccinepræparater indeholdende interleukiner DK0482076T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37974289A 1989-07-14 1989-07-14

Publications (1)

Publication Number Publication Date
DK0482076T3 true DK0482076T3 (da) 1995-07-17

Family

ID=23498494

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90911344.1T DK0482076T3 (da) 1989-07-14 1990-07-16 Stabile vaccinepræparater indeholdende interleukiner

Country Status (12)

Country Link
EP (1) EP0482076B1 (de)
JP (2) JP3485184B2 (de)
KR (1) KR0177179B1 (de)
AT (1) ATE121629T1 (de)
AU (1) AU648509B2 (de)
CA (1) CA2063587C (de)
DE (1) DE69018990T2 (de)
DK (1) DK0482076T3 (de)
ES (1) ES2075900T3 (de)
FI (1) FI104233B (de)
NO (1) NO301577B1 (de)
WO (1) WO1991001143A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991006319A1 (en) * 1989-10-27 1991-05-16 Arch Development Corporation Methods and compositions for promoting immunopotentiation
US6406696B1 (en) 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
GR1000881B (el) * 1990-08-06 1993-03-16 Praxis Biolog Inc Σταθερες συνθεσεις εμβολιου που περιεχουν ιντερλευκινες.
AU9161591A (en) * 1990-12-19 1992-07-22 Schering Corporation Use of il-4 to enhance immune response to immunogens in vaccines
WO1992020370A1 (en) * 1991-05-13 1992-11-26 Regents Of The University Of California Liposomal polysaccharide vaccines
DE4126983A1 (de) 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
AU688736B2 (en) * 1992-08-10 1998-03-19 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Interleukin-4 stimulated T lymphocyte cell death
ZA936095B (en) * 1992-08-21 1994-03-14 Univ Melbourne Cytokine applications.
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
AU3541495A (en) * 1994-09-01 1996-03-22 Wisconsin Alumni Research Foundation Therapeutic remodeling in aids
US6509313B1 (en) 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
AU724743B2 (en) 1996-05-31 2000-09-28 Genetics Institute, Llc IL-12 as an adjuvant for Bordetella Pertussis vaccines
TW586934B (en) * 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
US6270758B1 (en) 1998-10-08 2001-08-07 Duke University Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects
US6027731A (en) * 1998-11-17 2000-02-22 Wisconsin Alumni Research Foundation Pertussis toxin induced lymphocytosis
IT1302534B1 (it) 1998-12-21 2000-09-05 Fidia Advanced Biopolymers Srl Composizioni iniettabili, biocompatibili e biodegradabili comprendentialmeno un derivato dell'acido ialuronico, cellule condrogeniche, per
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
ATE413191T1 (de) 1999-12-03 2008-11-15 Celltech Chiroscience Ltd Verwendung of interleukin-1 mutein als impfstoffadjuvans
WO2007009064A2 (en) 2005-07-11 2007-01-18 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
EP1928418B1 (de) 2005-09-30 2011-12-21 Lipoxen Technologies Limited Liposomale impfstoff-zusammensetzung aus einem polysaccharid-antigen und einem protein-adjuvans
SG177907A1 (en) 2006-06-14 2012-02-28 Macrogenics Inc Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
CA2679720A1 (en) * 2007-03-09 2008-09-18 Merck & Co., Inc. Papillomavirus vaccine compositions
WO2014068085A1 (en) * 2012-11-02 2014-05-08 Cytuvax Composition comprising cytokine macro-aggregates
EA202190778A1 (ru) * 2018-10-12 2021-08-05 Серум Инститьют Оф Индия Прайват Лтд Композиция комбинированной вакцины, содержащая уменьшенную дозу инактивированного полиовируса, и способ её получения
CN113365650A (zh) 2018-11-16 2021-09-07 新免疫技术有限公司 用il-7蛋白和免疫检查点抑制剂的组合治疗肿瘤的方法
US20230057939A1 (en) 2020-01-13 2023-02-23 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and a bispecific antibody
JP2023512657A (ja) 2020-02-05 2023-03-28 ワシントン・ユニバーシティ Ｉｌ－７タンパク質とｃａｒ保有免疫細胞の組み合わせで固形腫瘍を治療する方法
KR20230098201A (ko) 2020-10-26 2023-07-03 네오이뮨텍, 인코퍼레이티드 줄기 세포 동원의 유도 방법
EP4236989A1 (de) 2020-11-02 2023-09-06 NeoImmuneTech, Inc. Verwendung von interleukin-7 zur behandlung des coronavirus
JP2023549112A (ja) 2020-11-05 2023-11-22 ネオイミューンテック， インコーポレイテッド Ｉｌ－７タンパク質とヌクレオチドワクチンの組み合わせで腫瘍を治療する方法
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
WO2023130081A1 (en) 2021-12-30 2023-07-06 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist
JP2026504619A (ja) 2022-11-07 2026-02-06 ネオイミューンテック， インコーポレイテッド 非メチル化ｍｇｍｔプロモーターを含む腫瘍を治療する方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2849632B2 (ja) * 1988-04-08 1999-01-20 社団法人北里研究所 ワクチン製剤
DE3818054C2 (de) * 1988-05-27 1994-02-17 Biotest Pharma Gmbh Verwendung einer Kombination aus einem Antigen bzw. einer Vakzine und humanem Interleukin zur Behandlung der Non-Responsiveness gegenüber immunologischen Defektzuständen
JPH0236129A (ja) * 1988-07-22 1990-02-06 Ajinomoto Co Inc ワクチン効果増強剤

Also Published As

Publication number Publication date
EP0482076A1 (de) 1992-04-29
CA2063587C (en) 2005-08-30
WO1991001143A1 (en) 1991-02-07
ATE121629T1 (de) 1995-05-15
KR0177179B1 (ko) 1999-03-20
AU6050090A (en) 1991-02-22
FI104233B1 (fi) 1999-12-15
DE69018990T2 (de) 1995-12-14
JP2004002463A (ja) 2004-01-08
CA2063587A1 (en) 1991-01-15
JPH04506663A (ja) 1992-11-19
JP3485184B2 (ja) 2004-01-13
AU648509B2 (en) 1994-04-28
ES2075900T3 (es) 1995-10-16
FI920132A0 (fi) 1992-01-13
EP0482076B1 (de) 1995-04-26
NO301577B1 (no) 1997-11-17
NO920161L (no) 1992-03-05
DE69018990D1 (de) 1995-06-01
NO920161D0 (no) 1992-01-13
KR920703103A (ko) 1992-12-17
FI104233B (fi) 1999-12-15

Similar Documents

Publication Publication Date Title
DK0482076T3 (da) Stabile vaccinepræparater indeholdende interleukiner
FI945483A0 (fi) Hepatiitti B - pinta-antigeenejä ja muita antigeenejä sisältäviä yhdistelmärokotteita
GB2210557B (en) Vaccine containing tumor antigens and refined detoxified endotoxin as an adjuvant.
MX9304089A (es) Uso de gm-csf como una vacuna adyuvante.
PT101052A (pt) Proteinas hibridas uteis na preparacao de vacinas
GB8403921D0 (en) Preparation of lyophilized adsorbed polyvalent vaccines
DK400181A (da) Sammensatte materialer indeholdende immobiliserede biologisk aktive arter fremgangsmaade til deres fremstilling samt deres anvendelse
CA2231603A1 (en) Chicken interleukin-15 and uses thereof
CO5070644A1 (es) Vacunas que comprenden proteinas e6 de hpv y/o e7 de hpv junto con un oligonucleotido cpg como adyudante
IT8322155A0 (it) Procedimento per immobilizzare materie biologiche e composto di materie biologiche adsorbite in vermiculite.
AU6979387A (en) Fusion protein comprising influenza virus haemagglutinin and antigenic epitope
DE3582272D1 (de) Antigenische zubereitungen und isolierung von solchen zubereitungen.
WO2001039803A3 (en) Interleukin-1 muteins useful as vaccine adjuvants
ES2111031T3 (es) Uso de preparaciones que contienen anticuerpos para la inmunosupresion.
CA2169297A1 (en) Protein- or peptide-cochleate vaccines and methods of immunizing using the same
ATE350390T1 (de) Synthetische peptide und impfstoffe welche diese beinhalten
NZ203190A (en) Vaccines of infections bronchitis virus
WO2001060404A3 (en) Use of opri lipoprotein from pseudomonas as a th1 inducing natural adjuvant for heterologous antigens
AU2415284A (en) Polypeptidic fractions inducing propective antibodies against malaria parasites and immunogenic compositions containing them
DK0538341T3 (da) EHV-4-gycoproteinvaccine.
JPS55106261A (en) Composition made of dispersed body of colloid silica and colloid titania
FI971402A7 (fi) Menetelmä voimistettujen antigeenisten Helico-bacter-lajien ja niitä s isältävien rokotteiden valmistamiseksi
GB8915572D0 (en) Use of bluetongue virus proteins as vaccine components
YU47377B (sh) Suspenzija zeolita koja sadrži sil ikonat
ATE44651T1 (de) Immunogene protein- oder peptidkomplexe enthaltende vakzine.